tirzepatide nash phase 3 Effect of versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, SURPASS-3 Tirzepatide: First Approval | Drugs

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

Eat well, feel great, and reach your health goals while on GLP-1 medications with this practical, science-backed cookbook

Safe, supervised, and designed to meet your health goals.

Complete cardiovascular benefits guide for Canadians

As with other agents in this class, semaglutide has a boxed warning regarding rodent thyroid C-cell tumor findings and the uncertain relevance to humans

For over two decades, GLP-1 has been heavily investigated as the most promising therapy target in type 2 diabetes patients